bluebird bio Inc. (NASDAQ:BLUE) saw a downside of -2.56% to close Monday at $3.42 after subtracting -$0.09 on the day. The 5-day average trading volume is 4,344,920 shares of the company’s common stock. It has gained $3.74 in the past week and touched a new high 4 times within the past 5 days. An average of 4,368,675 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,568,240.
BLUE’s 1-month performance is -15.56% or -$0.63 on its low of $3.11 reached on 08/14/23. The company’s shares have touched a 52-week low of $2.78 and high of $8.58, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, BLUE has lost -50.58% or -$3.50 and has reached a new high 6 times. However, the current price is down -60.14% from the 52-week high price.
Insider Transactions
BLUE stock investors last saw insider trading activity on Aug 10.Obenshain Andrew (President and CEO) most recently sold 16,929 shares at $3.54 per share on Aug 10. This transaction cost the insider $59,956., Klima Thomas J, sold 4,130 shares at a price of $3.50 on Jun 02. Then, on Jan 11, Director Leschly Nick sold 4,290 shares at a price of $7.80 per share. This transaction amounted to $33,480.
Valuation Metrics
BLUE stock has a beta of 0.91. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 38.36 while the price-to-book (PB) in the most recent quarter is 1.29.
bluebird bio Inc.’s quick ratio for the period ended June 29 was 2.00, with the current ratio over the same period at 2.10. In terms of profitability, the gross margin trailing 12 months is -37.80%. The trailing 12-month EBITDA margin is -10540.76%. The firm’s gross profit as reported stood at -$6.48 million against revenue of $3.6 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -37.35% to -$72.91 million, while revenue of $21.24 million was 129.13% off the previous quarter. Analysts expected BLUE to announce -$0.72 per share in earnings in its latest quarter, but it posted -$0.67, representing a 6.90% surprise. EBITDA for the quarter stood at more than -$84.33 million. BLUE stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 374.37 million, with total debt at $306.86 million. Shareholders hold equity totaling $106.95 million.
Let’s look briefly at bluebird bio Inc. (BLUE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 21 August was 43.58% to suggest the stock is trending Neutral, with historical volatility in this time period at 70.29%.
The stock’s 5-day moving average is $3.52, reflecting a -1.16% or -$0.04 change from its current price. BLUE is currently trading -10.94% above its 20-day SMA, -20.83% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -9.04% and SMA200 by-46.14%.
Stochastic %K and %D was 27.82% and 31.41% and the average true range (ATR) pointed at 0.33. The RSI (14) points at 45.79%, while the 14-day stochastic is at 24.41% with the period’s ATR at 0.33. The stock’s 9-day MACD Oscillator is pointing at -0.01 and -0.13 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for bluebird bio Inc. (NASDAQ: BLUE), BofA Securities upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for BLUE stock have a consensus rating for the stock as Hold. Currently, 2 brokerage advisors rate BLUE as a “sell,”, while 6 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 3 rates the stock as overweight while 2 have offered a “buy” rating.
What is BLUE’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.00 and a high of $11.00, with their median price target at $8.00. Looking at these predictions, the average price target given by analysts is for bluebird bio Inc. (BLUE) stock is $7.36.
